# Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

> **NCT01126749** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 92 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** E7389
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01126749
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-16
- **Primary completion:** 2015-05-08
- **Final completion:** 2016-07-20
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Study was terminated as per sponsor's decision
- **Last updated:** 2022-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126749, "Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01126749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*